Text Size

Cognitive Correlates of Antidepressant Treatment Response in Elders

This study has been completed.
Sponsor:
Information provided by:
St. Michael's Hospital, Toronto
ClinicalTrials.gov Identifier:
NCT01477268
First received: June 9, 2009
Last updated: November 18, 2011
Last verified: May 2011
History of Changes
  Purpose

Major depression is a very common health problem affecting older persons. The present standard of treatment is with medications called "antidepressants". Antidepressants have been studied extensively in older persons with normal brain function and have been shown to be effective. However, certain types of brain dysfunction called "executive impairment" (inability to do higher order thinking) may lead to poor treatment outcomes. This study will compare how older depressed people with different levels of executive impairment respond differently to standard antidepressant treatment. Knowing this information will lead to more rational targeting of available treatments, leading to improved treatment outcomes.


Condition Intervention Phase
Depression
 Drug: Zoloft (antidepressant)
 Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Determining the Impact of Dementia and Executive Impairment on Antidepressant Treatment Response in Older Persons

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by St. Michael's Hospital, Toronto:

Primary Outcome Measures:
  • depression [ Time Frame: June 1, 2007 - June 1, 2008 ] [ Designated as safety issue: No ]

Enrollment: 30
Study Start Date: June 2007
Study Completion Date: October 2009
Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
zoloft
Both arms of the study will include zoloft. However, the treatment response to zoloft will be compared in two different subgroups.
 Drug: Zoloft (antidepressant)
Zoloft 50-200 mg po od x 12 weeks
Other Name: Sertraline

  Eligibility

Ages Eligible for Study:   65 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • above the age of 65,
  • speak English fluently,
  • experience depression, AND
  • not yet on active treatment.

Exclusion Criteria:

  • active delirium,
  • substance abuse,
  • mental illness other than major depression,
  • active CNS disease,
  • unstable systematic medical disease, OR
  • current of past psychotic disorder.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01477268

Locations
Canada, Ontario
St Michael's Hospital
Toronto, Ontario, Canada, M5B 1W8
Sponsors and Collaborators
St. Michael's Hospital, Toronto
Investigators
Principal Investigator: Corinne Fischer, MD St. Michaels Hospital
  More Information

No publications provided

Responsible Party: Dr. Corinne E. Fischer, St. Michael's Hospital
ClinicalTrials.gov Identifier: NCT01477268     History of Changes
Other Study ID Numbers: 06-296
Study First Received: June 9, 2009
Last Updated: November 18, 2011
Health Authority: Canada: Ethics Review Committee

Keywords provided by St. Michael's Hospital, Toronto:
antidepressants
depression
zoloft
psychiatry
psychology

Additional relevant MeSH terms:
Depression
Depressive Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders
Antidepressive Agents
Sertraline
Psychotropic Drugs
Central Nervous System Agents
 Therapeutic Uses
Pharmacologic Actions
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Serotonin Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 21, 2013